Answers are grounded in this paper and cite their sources.
Discusses the 2023 updated AGS Beers Criteria regarding the comparison of rivaroxaban and apixaban in older adults.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: